This Is What Whales Are Betting On Snowflake
read more
Hemp Donations Fuel DeSantis And Florida GOP’s Charge Against Weed Legalization, New Findings
As Americans are preparing to head to the polls on Nov.5 to decide the winner in the 2024 race for the White House, Floridians are about to weigh in on recreational cannabis legalization as well. Meanwhile, GOP Gov. Ron DeSantis has been leading the anti-marijuana charge in a months-long heated debate. The governor and the Republican Party of Florida have found a common language with hemp companies that already sell high-potency cannabis to Floridians, at least when it comes to opposition to a proposed constitutional amendment to legalize recreational marijuana in the state.According to a Miami Herald/Times investigation, the Republican Party of Florida and a political committee run by DeSantis' chief of staff have acquired donations from such businesses after the governor vetoed a bill that would have banned certain intoxicating hemp-derived products in the state in June. That bill would have outlawed the sale of products containing delta-8 THC and limited the amount of delta-9 THC, both of which are unregulated and widely available, including to minors.
read more
Bitcoin, Ethereum Wobble As Election Results Loom, But Dogecoin Surges: Expect ‘Brutal’ Price Action In The Next 48 Hours, Trader Warns
Cryptocurrency markets are trading lower on the day before the presidential election.
read more
Applied Materials and Lam Research Shift Supply Chains Away from China to Meet New US Guidelines
US semiconductor industry excludes Chinese firms from supply chains, increasing costs but ensuring national security, as US tightens trade policies.
read more
Did Elon Musk Change His Mind On Celebrity Endorsements? Tesla Signs Deal With Viral Olympian In This Country
Tesla was against advertising for years but is now okay with the practice. Did the company also change its mind about celebrity endorsements?
read more
This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Latest Ratings for BAH
DateFirmActionFromTo Mar 2022B of A SecuritiesUpgradesUnderperformNeutral Feb 2022Morgan StanleyMaintainsOverweight Jan 2022B of A SecuritiesDowngradesBuyUnderperform
View More Analyst Ratings for BAH
View the Latest Analyst Ratings
read more
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment.
Latest Ratings for NKTR
DateFirmActionFromTo Mar 2022OppenheimerUpgradesPerformOutperform Nov 2021BenchmarkUpgradesHoldBuy Nov 2021SVB LeerinkMaintainsMarket Perform
View More Analyst Ratings for NKTR
View the Latest Analyst Ratings
read more
